Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH

Trial Profile

Open Label Extension Study of Eculizumab in Patients With Transfusion Dependent PNH

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Mar 2018

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Adverse reactions
  • Sponsors Alexion Pharmaceuticals
  • Most Recent Events

    • 08 Jun 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top